Arzerra Chemotherapy Information

Adults who have been diagnosed with chronic lymphocytic leukemia (CLL) may benefit from Arzerra^® (ofatumumab). This prescription medicine is approved for use in people who have not adequately responded to certain other chemotherapy treatment. Although the medicine has not been shown to decrease symptoms or prolong survival, one clinical study showed that some people who had failed other treatments had at least a partial response to Arzerra.

 

Arzerra comes as an intravenous (IV) infusion that is administered by a healthcare provider in a healthcare setting. The infusion is given once a week for eight weeks, followed by a dose every four weeks for four doses.

 

Before beginning chemotherapy treatment with Arzerra, make sure to review the medication's safety information with your healthcare provider. For example, you may not be able to use this medicine if you have a history of hepatitis B, lung disease, or a bowel obstruction. Also, this drug may react with various other medications.